Reset filters
Publication Types
2 May 2022

Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is one of the deadliest pulmonary conditions and is associated with poor survival and high morbidity (1). The disease is characterized by abnormalities in both the lung interstitium and pulmonary vasculature, which has made finding a treatment challenging (2, 3)...

IDDI Workstream or Task Force Learning
17 February 2022

Pulmonary hypertension (PH) is a multifactorial chronic pulmonary disease. During the past decade, various pathophysiological pathways eventually leading to progressive pulmonary vascular remodelling have been detected...

IDDI Workstream or Task Force Learning
24 September 2021

Pulmonary hypertension (PH) is a frequent finding in advanced COPD. Usually pulmonary pressure is only mildly elevated, but a subgroup of patients develops severe PH, arbitrarily defined as mean pulmonary pressure (mPAP) ≥35 mmHg)...

IDDI Workstream or Task Force Learning
12 April 2021

Reports documenting the presence and impact of pulmonary hypertension (PH) complicating lung disease date back to the early 1980s. Ever since effective therapies for group 1 pulmonary arterial hypertension started to emerge in the 1990s with IV epoprostenol, through the early 2000s with the endothelin receptor antagonists and PDE-5 inhibitors, there has been increasing interest in the potential role of these therapies for PH beyond group 1 disease (1)...

IDDI Workstream or Task Force Learning